<DOC>
	<DOCNO>NCT01252069</DOCNO>
	<brief_summary>This long-term extension phase III , efficacy safety open-label ( protocol PGL09-026 ) PGL4001 10mg tablet daily three month , blind towards administration progestin placebo tablet end PGL4001 treatment . This extension study consist three period 3 month open-label PGL4001 treatment , follow ten day double-blind treatment progestin placebo period without treatment .</brief_summary>
	<brief_title>PGL4001 Efficacy Assessment Reduction Symptoms Due Uterine Leiomyomata ( PEARLIII-extension Study )</brief_title>
	<detailed_description />
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Progestins</mesh_term>
	<criteria>Subject complete visit 6 PGL09026 study , 10 18 day menstruation follow end treatment PGL4001 , take medication forbid protocol . Subject large uterine polyp ( &gt; 2cm ) . Subject one ovarian cysts â‰¥ 4cm diagnose ultrasound PGL09026 study . Subject abnormal hepatic function retest . Subject clinically significant abnormal finding visit A medical condition ( ) laboratory finding , opinion investigator , might jeopardize subject 's safety interfere study evaluation . Subject positive pregnancy test planning pregnancy course study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>